The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy’s said in a statement.
Also Read: Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added.
“The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development,” Dr Reddy’s CEO Erez Israeli said.
He further said:”With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients.”
The Canada launch builds on the momentum of the company’s recent launch in India under the brand name Obeda, Israeli said.”As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets,” he noted.
In Canada, Dr Reddy’s Semaglutide injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise, the company said.
It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml.
The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection, the statement said.